Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
MESO
MESO
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
MESO News
Ryoncil Demonstrates High Survival Rates in Acute GVHD Treatment
3d ago
Benzinga
Mesoblast Reports Ryoncil® Treatment Data for SR-aGvHD
3d ago
Newsfilter
Mesoblast Reports Strong Q2 Performance and Financing Update
Jan 29 2026
Newsfilter
Mesoblast Reports Strong Q2 Performance with Ryoncil Sales Surge
Jan 29 2026
Yahoo Finance
Mesoblast Limited Receives FDA Feedback on BLA Filing for Rexlemestrocel-L in Chronic Low Back Pain
Jan 20 2026
Benzinga
Mesoblast Receives FDA Feedback for BLA Filing of rexlemestrocel-L
Jan 19 2026
NASDAQ.COM
Mesoblast Receives FDA Feedback on BLA Filing for rexlemestrocel-L in Chronic Low Back Pain
Jan 19 2026
Globenewswire
Exelixis Reports Preliminary 2025 Revenue of $2.123 Billion, Shares Drop 4.6%
Jan 12 2026
Benzinga
Mesoblast Reports 60% YoY Growth in Ryoncil Sales to $35.1 Million
Jan 09 2026
Benzinga
Mesoblast Reports 60% Quarterly Sales Growth for Ryoncil, Shares Jump 8%
Jan 09 2026
NASDAQ.COM
Mesoblast Reports 60% Revenue Growth to $35.1 Million in Q4
Jan 09 2026
Globenewswire
Mesoblast (MESO) Chair Jane Bell Announces Retirement
Jan 02 2026
Yahoo Finance
Mesoblast Appoints New Chair to Strengthen U.S. Market Strategy
Jan 02 2026
NASDAQ.COM
Mesoblast Appoints New Chair to Drive Commercialization Efforts
Jan 01 2026
Globenewswire
Mesoblast Secures $125 Million Credit Facility to Lower Capital Costs
Dec 30 2025
Globenewswire
Mesoblast Secures $125 Million Financing Option to Support Strategic Development
Dec 30 2025
Newsfilter
Show More News
